Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sundance Resources Limited		
ABN		

19 055 719 394

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1) 93,333,334 shares
- 2) 49,333,334 unlisted options
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1) Fully paid ordinary shares
- Unlisted options exercisable at \$0.006 per option

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.00375 per share – 26,666,667 shares \$0.0045 per share – 66,666,667 shares
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Financial support as per agreement.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the</i> +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 November 2019
6c	Number of *securities issued without security holder approval under rule 7.1	93,333,334 shares
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
Ot.		T N L / A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining		
Oi	issue capacity under rule 7.1	7.1 <b>– 1,220,585,375</b>	
	and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1A — <b>806,168,027</b>	
_			
7	+Issue dates	16 December 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Closs
Ω	Number and taless of all	Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	9,221,846,954	Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
260,000,000	Unquoted Investor Consortium Options exercisable at \$0.0695 per share
200,000,000	Unquoted Noble Options exercisable at \$0.0695 per option
260,000,000	Unquoted Wafin Options exercisable at \$0.0695 per option
100,000,000	Unquoted 2017 Options exercisable at \$0.003 per option expiring 7 April 2022
100,000,000	Unquoted 2017 Options exercisable at \$0.006 per option vesting 1 December 2018 and expiring on 7 April 2023
110,000,000	Unquoted Options exercisable at \$0.006 per option expiring 8 January 2024
400,000,000	Unquoted Options exercisable at \$0.006 per option expiring 13 February 2024
30,000,000	Unquoted Options exercisable at \$0.006 per option expiring 21 February 2024
26,666,667	Unlisted Options exercisable at \$0.006 per option expiring 28 August 2024
22,666,667	Unlisted Options exercisable at \$0.006 per option expiring 29 August 2024
Total unlisted options: 1,509,333,334	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Number +Class 9 Number and +class of all Noble Convertible Notes \*securities not quoted on ASX 200,000 (including the +securities in Investor Consortium 240,000 section 2 if applicable) Convertible Notes Wafin Convertible Notes 400.000 2015 Investor Group 70,000 Convertible Notes 2016 Investor Group 2,600 Convertible Notes **Total Convertible** Notes: 912,600 10 Dividend policy (in the case of a N/A trust, distribution policy) on the increased capital (interests) Part 2 - Pro rata issue 11 Is security holder approval N/A required? 12 Is the issue renounceable or non-N/A renounceable? 13 Ratio in which the \*securities will N/A be offered 14 \*Class of \*securities to which the N/A offer relates 15 \*Record N/A date to determine entitlements 16 holdings on different N/A registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements N/A in relation to fractions

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

31	How do security holders sell part of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A

<sup>+</sup> See chapter 19 for defined terms.

Part 3 - Quotation of securities

### You need only complete this section if you are applying for quotation of securities 34 Type of +securities (tick one) (a) \*Securities described in Part 1 (b) All other +securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of 35 the additional \*securities, and the number and percentage of additional \*securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional \*securities Entities that have ticked box 34(b) 38 Number of \*securities for which \*quotation is sought 39 +Class of +securities for which quotation is sought

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- †Quotation of our additional \*securities is in ASX's absolute discretion. ASX may quote the \*securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Date: 17 December 2019

Print name: CA

CAROL MARINKOVICH

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base fig capacity is calculated	Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	8,375,846,952	
<ul> <li>Add the following:</li> <li>Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid *ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> <li>Subtract the number of fully paid *ordinary securities cancelled during that</li> </ul>	Issued under Listing Rule 7.2  Nil  Ratified / Approved at AGM 30/1/19  16 October 2018 – 62,500,000  Ratified / Approved at AGM 29/11/19  9 January 2019 – 55,000,000  14 February 2019 – 200,000,000  22 February 2019 – 15,000,000  8 April 2019 – 300,000,000  12 July 2019 – 53,333,333  6 August 2019 – 26,666,667	
12 month period  "A"	9,088,346,952	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15	1,363,252,043
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	

**Insert** number of \*equity securities issued or agreed to be issued in that 12 month period *not counting* those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4

#### Note:

- This applies to equity securities, unless specifically excluded – not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

### **Placement Capacity**

- 16 December 2019 93,333,334 shares
- 16 December 2019 26,666,667
   Unlisted options at \$0.006 per option expiring 28 August 2024
- 16 December 2019 22,666,667
   Unlisted options at \$0.006 per option expiring 29 August 2024

**"C"** 142,666,668

## Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15  Note: number must be same as shown in Step 2	1,363,252,043
Subtract "C"  Note: number must be same as shown in Step 3	142,666,668
<b>Total</b> ["A" x 0.15] – "C"	1,220,585,375 [Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"D"	0.10  Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	908,834,695
7.1A that has already been used  Insert number of +equity securities issued or agreed to be issued in that 12 month	Ratified / Approved at AGM 29 November 2019
<ul> <li>Poeriod under rule 7.1A</li> <li>Notes: <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security</li> </ul> </li> </ul>	<ul> <li>5 September 2019 – 53,333,334</li> <li>24 September 2019 - 22,666,667</li> <li>14 October 2019 – 26,666,667</li> </ul>
<ul> <li>holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	908,834,695	
Subtract "E"  Note: number must be same as shown in Step 3	102,666,668	
<i>Total</i> ["A" x 0.10] – "E"	806,168,027  Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.